文献速递慢性肾脏病

慢性肾脏病贫血的治疗标准

Anaemia in CKD-treatment standard.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

本文综述慢性肾脏病贫血的发病机制与治疗标准。其发病涉及促红细胞生成素不足、铁缺乏、炎症等多因素;治疗以红细胞生成刺激剂(ESA)联合铁剂为主,早期CKD铁缺乏者单用铁剂可能足够;缺氧诱导因子脯氨酰羟化酶抑制剂为新型口服药物,高效但长期安全性受关注。

要点

  • CKD贫血发病多因素,主要包括病变肾脏促红细胞生成素产生不足。
  • ESA联合铁剂是主要治疗方式,因hepcidin升高常需静脉补铁。
  • 早期CKD铁缺乏者单用铁剂可能改善贫血,延迟ESA治疗需求。

核心结论

  • CKD贫血治疗以ESA联合铁剂为标准,HIF-PHI为新型口服药物但长期安全性受关注。

研究设计与样本

  • 本文为综述,回顾CKD贫血当前治疗标准及近期新进展。

主要发现

  • CKD贫血发病多因素,主要由病变肾脏促红细胞生成素产生不足所致,铁缺乏、炎症、红细胞寿命缩短和失血增加也为 Contributing 因素。
  • hepcidin水平升高限制肠道铁吸收,故铁剂常经静脉给药。
  • 早期CKD合并铁缺乏者,单用铁剂可能足以改善贫血,延迟ESA治疗需求。
  • HIF-PHI为口服活性药物,上调内源性促红细胞生成素产生及多个铁调节基因,可能增强红细胞生成。

关键数值与推荐

  • 使用ESA和铁剂前应排除并尽可能纠正其他贫血原因。
  • HIF-PHI高效,可能在导致传统ESA抵抗的炎症状态下有优势,但尤其长期安全性存在担忧。

临床怎么用

  • CKD贫血治疗主要采用ESA联合铁剂,铁剂常因hepcidin升高而静脉给药。
  • 早期CKD铁缺乏者单用铁剂可能改善贫血,延迟ESA需求。
  • 使用ESA和铁剂前应排除并尽可能纠正其他贫血原因。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaemia is one of the most common complications of chronic kidney disease (CKD), having a significant impact on quality of life, and is also associated with a number of adverse clinical outcomes. Its pathogenesis is multifactorial, caused largely by an inadequate production of erythropoietin from the diseased kidneys, with iron deficiency, inflammation, shortened red cell lifespan and enhanced blood loss also being contributory factors. The management of this condition was transformed in the late 1980s by the advent of recombinant human erythropoietin (epoetin), and treatment paradigms have developed over the last three decades, largely focusing on a combination of epoetin or its analogues (erythropoiesis-stimulating agents; ESAs) along with iron supplementation, often administered intravenously due to increased hepcidin levels limiting iron absorption from the gut. Indeed, in patients with early CKD and iron deficiency, iron per se may be sufficient to improve the anaemia, delaying the need for ESA therapy. Other causes of anaemia should be excluded and corrected (if possible) before resorting to treatment with ESAs and iron. More recently, the hypoxia-inducible factor-prolyl hydroxylase inhibitors have entered the therapeutic arena; these are orally active agents that upregulate endogenous erythropoietin production as well as a number of iron-regulatory genes which may also enhance erythropoiesis. The latter drugs are highly efficacious, and may have advantages in inflammatory conditions causing resistance to conventional ESA therapy, but concerns exist regarding their safety, particularly in the longer term. This article reviews the current standards of treatment, as well as recent novel developments in the management of anaemia in CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Macdougall IC. Anaemia in CKD-treatment standard. Nephrol Dial Transplant. 2024. PMID: 38012124. doi:10.1093/ndt/gfad250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。